| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 23rd November 2020 | Advisors Llc Perceptive | 500,000 | Open or private purchase | $12.85 | $6,425,000.00 |
| 12th November 2020 | Alexandria Forbes | 7,851 | Open or private sale | $15.01 | $117,843.51 |
| 11th November 2020 | Alexandria Forbes | 2,498 | Open or private sale | $15.02 | $37,519.96 |
| 10th November 2020 | Stuart Naylor | 3,739 | Open or private sale | $15.00 | $56,085.00 |
| 10th November 2020 | Alexandria Forbes | 12,703 | Open or private sale | $15.05 | $191,180.15 |
| 9th November 2020 | Stuart Naylor | 512 | Open or private sale | $15.00 | $7,680.00 |
| 5th November 2020 | Alexandria Forbes | 3,981 | Open or private sale | $15.03 | $59,834.43 |
| 5th November 2020 | Stuart Naylor | 8,282 | Open or private sale | $15.02 | $124,395.64 |
| 29th October 2020 | Joel S Marcus | 50,000 | Bona fide gift | $0.00 | |
| 27th October 2020 | Advisors Llc Perceptive | 3,000,000 | Open or private purchase | $10.00 | $30,000,000.00 |
Meira G Tx Holdings Plc
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
MeiraGTx Holdings Plc is a clinical-stage biotech company. It engages in the development of novel gene therapy treatments. The company was founded on March 20, 2015 and is headquartered in New York, NY.
Ticker: MGTX
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1735438
Employees: 157
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $195 M (-14%)
Other Assets, Current: $2 M (-5%)
Assets, Current: $235 M (-12%)
Property, Plant and Equipment, Net: $28 M (16%)
Other Assets, Noncurrent: $194 Th (0%)
Assets: $291 M (-10%)
Accounts Payable, Current: $3 M (-17%)
Accrued Liabilities, Current: $18 M (0%)
Liabilities, Current: $47 M (-5%)
Liabilities: $118 M (-11%)
Common Stock, Value, Issued: $1 Th (1%)
Common Stock, Shares, Issued: $37 M (1%)
Retained Earnings (Accumulated Deficit): $244 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $3 M (48%)
Stockholders' Equity (Parent): $173 M (0%)
Liabilities and Equity: $291 M (-10%)
Revenue: $2 M (-62%)
Research and Development: $16 M (-33%)
General and Administrative Expenses: $11 M (-50%)
Operating Income/Loss: $25 M (-38%)
Provision for income taxes: $91 Th (0%)
News
MeiraGTx Announces Pricing of Public Offering of Ordinary Shares
19th November 2020
MeiraGTx Announces Proposed Public Offering of Ordinary Shares
18th November 2020
MeiraGTx to Present at the Barclays Gene Editing & Gene Therapy Summit
10th November 2020
